摘要
目的:探讨肿瘤石蜡组织中ERCC1 codon118单核苷酸多态性(single nucleotide polymorphism,SNP)与接受铂类药物化疗非小细胞肺癌(chemotherapy;non-small-cell lung cancer,NSCLC)患者临床预后之间的关系。方法:采用聚合酶链反应-限制性内切酶片段长度多态性(PCR-RFLP)的方法评价47例石蜡包埋NSCLC肿瘤组织中DNA修复基因ERCC1第118位密码子的单核苷酸多态性,并比较不同基因型与NSCLC组织临床病理及铂类化疗预后之间的关系。结果:所有NSCLC患者中位生存时间为16.0月(95%CI,16.4-28.4月),中位无进展生存期为8.0月(95%CI,9.4-16.9月)。ERCC1 codon118与NSCLC临床病理特征均未见相关性。携带ERCC1 C/C基因型的NSCLC患者的中位总生存时间为25.0月,而携带C/T及T/T基因型患者的中位总生存时间仅为10.5月,两者有统计学差异(P=0.012)。携带ERCC1 C/C基因型的NSCLC患者的中位无进展生存期为13.2月,而携带C/T及T/T基因型患者的中位无进展生存期仅为6.0月,两者有统计学差异(P=0.029)。结论:ERCC1 codon118基因单核苷酸多态性与接受铂类药物化疗的NSCLC患者的总生存时间和无进展生存期有关,在一定程度上可以作为判断NSCLC患者铂类药物化疗的预后指标。
Objective：ERCC1 is emerging as essential elements in repairing platimun-DNA adducts.The aim of this study is to investigate whether the single nucleotide polymorphism（SNP） in Excision repair cross-complementation group 1（ERCC1） 118C→T is associated with the clinical prognosis of platinum-based chemotherapy in non-small-cell lung cancer.Methods： SNP of ERCC1 118C→T was genotyped by PCR-restrictive fragment length polymorphism（PCR-RFLP）.The pathological parameters and survival data were evaluated according to the different genotypes in 47 NSCLC patients.Results： ERCC1 118C→T was not related to clinic pathological parameters in NSCLC（P0.05）.The median survival of patients with C/C genotypes was 25.0 months compared to 10.5 months of C/T or T/T genotypes（P=0.012）.In Cox regresssion models,ERCC1 118C→T was significantly associated with overall survival time of NSCLC patients（P=0.015）.Conclusion： ERCC1 codon118 SNP might be a predictive marker of survival for NSCLC patients receiving platinum-based chemotherapy.
出处
《现代肿瘤医学》
CAS
2011年第10期1997-2001,共5页
Journal of Modern Oncology
基金
江苏省卫生厅项目(编号:H201035)
